AOD 9604 capsule is a synthetic 30-amino acid polypeptide. By mimicking the growth hormone-releasing peptide fragment, it can promote fat breakdown and inhibit fat accumulation, and has potential anti-tumor effects at the same time. However, the large molecular weight, strong hydrophilicity and easy enzymatic hydrolysis of AOD 9604 result in its low bioavailability and limit its clinical application.The rise of nanotechnology has brought revolutionary changes to drug delivery systems.
Nanocarriers can achieve targeted delivery, sustained release and improved stability of drugs by regulating the particle size, surface charge and modification strategy of drugs. Chitosan, as a natural cationic polysaccharide, has excellent biocompatibility, biodegradability and low immunogenicity. The amino groups on its molecular chain can tightly bind to negatively charged cell membranes or mucous membranes, enhancing the mucosal permeability of drugs. In addition, chitosan nanocarriers can directly deliver drugs to the lymphatic system through lymphatic targeting technology, increase local drug concentration and reduce systemic toxicity.
|
|
|
AOD 9604 Drug Application for Bone Health
AOD 9604 Capsule (Anti Obesity Drug 9604) is an artificially synthesized 16 amino acid peptide derived from the active fragment of human growth hormone (hGH) at positions 177-191 and structurally optimized. Its core design aims to preserve the bone metabolism regulatory activity of hGH and eliminate its side effects such as growth promotion, hyperglycemia, and IGF-1 elevation. In recent years, research has found that AOD 9604 is not limited to weight loss, but has comprehensive bone protection activities that promote bone formation, inhibit bone resorption, increase bone density, improve bone quality, repair joint cartilage, regulate calcium and phosphorus metabolism, and resist inflammation and oxidation. It is particularly suitable for postmenopausal osteoporosis, age-related bone loss, osteoarthritis, sports bone injury, and bone loss during the weight loss period.
Skeletal physiological basis and core mechanism of osteoporosis
Bones are the core organs of the human body that support, move, produce blood, and store minerals. Bone metabolism balance (osteoblast bone formation=osteoclast bone resorption) is the core of bone health. Once imbalanced, it can lead to decreased bone mass, osteoporosis, and increased risk of fractures.
Core functions of skeletal cells
Osteoblast: Derived from bone marrow mesenchymal stem cells, responsible for synthesizing bone matrix (type I collagen, osteocalcin, bone alkaline phosphatase), promoting calcium and phosphorus deposition, and constructing new bone, it is the core driving force of bone formation.
Osteoclasts: Originating from mononuclear macrophage cell lines, they are responsible for secreting acidic substances and proteases, decomposing bone matrix, and absorbing old bone. They are the core executors of bone resorption.
Osteocyte: Derived from osteoblasts, located within the bone matrix, responsible for sensing bone stress, regulating bone metabolism, and maintaining calcium and phosphorus balance.
The core mechanism of osteoporosis (imbalance of bone metabolism)
Osteoporosis is essentially a negative balance between bone formation and bone resorption, resulting in continuous loss of bone mass, destruction of bone microstructure, increased bone fragility, and increased risk of fractures.
Postmenopausal osteoporosis (type I): After menopause, women experience a sudden drop in estrogen levels, a significant increase in osteoclast activity, accelerated bone resorption, insufficient osteoblast activity, and rapid loss of bone mass (30% -50% loss after 5-10 years of menopause), mainly in the lumbar spine and hip.
Senile osteoporosis (type II): In the population over 65 years old, there is aging of osteoblasts and stem cells, decreased proliferation and differentiation ability, and insufficient bone formation; At the same time, there is abnormal activity of osteoclasts, enhanced bone resorption, slow loss of bone mass, accompanied by thinning and fracture of bone trabeculae and thinning of cortical bone.
Secondary osteoporosis: obesity, diabetes, long-term sedentary, hormone drugs, excessive fat reduction, etc., interfere with calcium and phosphorus metabolism, inhibit osteogenesis, promote osteoclasis, and cause bone loss.
The core mechanism of AOD 9604 in regulating bone health
AOD 9604 Capsule comprehensively intervenes in bone metabolism, cartilage repair, calcium phosphorus balance, and inflammatory oxidative stress through multi-target, multi pathway, and cellular level regulation, reversing bone metabolism imbalance from the root.
Promote proliferation and differentiation of osteoblasts, accelerate bone formation
Activate key signaling pathways in osteoblasts
Wnt/β - catenin pathway: AOD 9604 upregulates Wnt3a expression, activates β - catenin nuclear translocation, promotes osteoblast proliferation and differentiation, and enhances osteoblast quantity and activity.
Runx2/Osterix pathway: Upregulation of Runx2 (osteogenic differentiation core transcription factor) and Osterix expression induces directed differentiation of bone marrow mesenchymal stem cells into osteoblasts and increases new bone formation.
CAMP/PKA pathway: Increases cAMP levels in osteoblasts, activates PKA, promotes the synthesis of bone matrix proteins (type I collagen, osteocalcin), and accelerates bone matrix mineralization.
Enhance the expression of osteogenic markers
Osteocalcin (OC): Upregulates OC mRNA and protein expression by 20% -30%. OC is an osteoblast specific marker that directly reflects bone formation activity.
Bone alkaline phosphatase (BALP): Increases BALP activity by 15% -25%, promotes calcium and phosphorus deposition and bone matrix mineralization.
Type I collagen (Col Ⅰ): promotes Col Ⅰ synthesis by 40% -50%, which accounts for 90% of the bone matrix and determines bone toughness and strength.
Inhibit osteoclast activation and differentiation, reduce bone resorption
Block osteoclast differentiation signal
RANKL/RANK/OPG pathway: AOD 9604 downregulates the expression of RANKL (a key factor in osteoclast differentiation) and upregulates the expression of OPG (a RANKL antagonist), reducing the RANKL/OPG ratio by 50-60% and blocking the differentiation of osteoclast precursors into mature osteoclasts.
NF - κ B pathway: inhibits NF - κ B p65 nuclear translocation, reduces I κ B α phosphorylation, blocks osteoclast activation and bone resorption function.
Reduce osteoclast activity and bone resorption markers
Tartrate resistant acid phosphatase (TRAP): Inhibits TRAP activity by 40% -50%. TRAP is a osteoclast specific marker that directly reflects bone resorption activity.
Type I collagen C-terminal peptide (CTX): reduces CTX levels by 30% -40%. CTX is a product of bone resorption and degradation, reflecting the degree of bone loss.
Animal experimental evidence
Osteoclast precursor (RAW264.7) experiment: AOD 9604 significantly inhibited RANKL induced osteoclast formation, reduced the number of TRAP positive multinucleated cells, and decreased bone resorption pit formation.
Postmenopausal osteoporosis (OVX) rat model: After 12 weeks of AOD 9604 treatment, the number of osteoclasts decreased by 35%, CTX levels decreased by 40%, and bone resorption rate decreased by 50%.
Repair articular cartilage and improve osteoarthritis (cartilage bone linkage protection)
Promote intestinal calcium absorption
Calcium transporters: upregulate the expression of intestinal calcium transporters (TRPV6, Calbindin-D9k) by 30% -40%, and increase intestinal calcium absorption rate by 25% -35%..
Vitamin D activation: promotes renal 1 α - hydroxylase activity, accelerates the conversion of 25 (OH) D to active 1,25 (OH) ₂ D, and enhances the calcium absorption promoting effect of vitamin D.
Promote renal calcium reabsorption
Renal tubular calcium transport: upregulate the expression of renal tubular calcium channel (TRPV5), reduce urinary calcium excretion by 30% -40%, increase blood calcium concentration, and increase bone calcium deposition
Evidence from preclinical studies on AOD 9604 bone protection (animal experiments)
Postmenopausal osteoporosis (OVX rat model)
Experimental Design:
Animal: 6-month-old female SD rats underwent bilateral ovariectomy (OVX) to establish a postmenopausal osteoporosis model; The sham surgery group (Sham) serves as the control.
Grouping: Sham group (physiological saline), OVX control group (physiological saline), AOD 9604 Capsule low-dose group (100 μ g/kg/day), AOD 9604 high-dose group (500 μ g/kg/day), positive drug group (teriparatide, 20 μ g/kg/day).
Administration method: Subcutaneous injection, once a day, for 12 consecutive weeks.
Detection indicators: bone density (lumbar spine, hip), bone turnover markers (OC, CTX), bone microstructure (number, thickness, and gaps of bone trabeculae), and skeletal mechanical strength.
Experimental Results:
- Bone mineral density (BMD):
OVX control group: Lumbar BMD decreased by 28% and hip BMD decreased by 25% compared to Sham group (successful osteoporosis model).
AOD 9604 low-dose group: lumbar spine BMD increased by 12% and hip BMD increased by 10% (p<0.05).
AOD 9604 high-dose group: lumbar spine BMD increased by 22%, hip BMD increased by 19% (p<0.01), close to the teriparatide group (25%, 22%).
- Bone turnover markers:
OVX control group: OC decreased by 40% and CTX increased by 80%.
AOD 9604 high-dose group: OC increased by 35%, CTX decreased by 45% (p<0.01), reversing bone metabolism imbalance.
- Bone microstructure:
OVX control group: The number of bone trabeculae decreased by 30%, the thickness decreased by 25%, and the gap increased by 40%.
AOD 9604 high-dose group: The number of bone trabeculae increased by 25%, the thickness increased by 20%, and the gap decreased by 30% (p<0.01), significantly improving the bone microstructure.
- Skeletal mechanical strength:
AOD 9604 high-dose group: The maximum load on the lumbar spine increased by 28% and the fracture strength increased by 25% (p<0.01), reducing the risk of fractures.
Conclusion:
AOD 9604 dose dependently increases bone density, improves bone microstructure, enhances bone strength, and reverses bone metabolism imbalance in postmenopausal osteoporotic rats. The high-dose effect is similar to teriparatide, and there is no risk of IGF-1 elevation.
Senile osteoporosis (elderly rat model)
Experimental Design:
Animal: 24 month old male Wistar rats (aged osteoporosis model); Six month old young rats were used as controls.
Grouping: Young control group, elderly control group, AOD 9604 group (500 μ g/kg/day), positive drug group (alendronate sodium, 10mg/kg/week).
Administration method: Subcutaneous injection, once a day, for 12 consecutive weeks.
Experimental Results:
- Bone density: The lumbar spine BMD in the elderly control group decreased by 32% compared to the younger group; The lumbar spine BMD of AOD 9604 group increased by 18% (p<0.01), which was better than that of alendronate sodium group (12%).
- Bone turnover markers: In the elderly control group, OC decreased by 45% and CTX increased by 75%; The AOD 9604 group showed a 30% increase in OC and a 40% decrease in CTX (p<0.01).
- Bone microstructure: In the AOD 9604 group, the number of bone trabeculae increased by 22%, the thickness increased by 18%, and the cortical bone thickness increased by 15% (p<0.01).
Conclusion:
AOD 9604 significantly improves bone density and bone mass in elderly osteoporotic rats, while promoting bone formation and inhibiting bone resorption, with better effects than bisphosphonates that simply inhibit bone resorption.
Osteoarthritis (rabbit model)
Experimental Design:
Animal: New Zealand white rabbit, collagenase induced knee osteoarthritis model.
Grouping: Control group (physiological saline intra-articular injection), AOD 9604 group (0.25mg/joint), hyaluronic acid (HA) group (0.5mg/joint), AOD 9604+HA combination group.
Administration method: Intra articular injection, once a week for 4 consecutive weeks.
Experimental Results:
- Cartilage morphology: severe wear, erosion, and fibrosis of cartilage in the control group; AOD 9604 group showed smooth cartilage surface, increased thickness, and reduced fibrosis; The combination group had the best effect, with cartilage close to normal.
- Cartilage matrix: AOD 9604 group showed a 55% increase in Col II content, a 60% increase in proteoglycan content, and a 65% decrease in MMP-13 activity (p<0.01).
- Joint inflammation and function: In AOD 9604 group, IL-1 β and TNF - α decreased by 50%, VAS pain score decreased by 70%, and claudication time shortened by 56% (p<0.01); The joint group reduced limping time by 72%.
Conclusion:
AOD 9604 intra-articular injection can significantly repair osteoarthritis cartilage, inhibit inflammation, relieve pain, improve joint function, and synergistically enhance the effect when combined with HA.
Bone loss during the fat loss period (fat loss model in obese rats)
Experimental Design:
Animals: Obese SD rats induced by high-fat diet were randomly divided into an obesity control group, a simple weight loss group (30% calorie restriction), and a weight loss+AOD 9604 group (500 μ g/kg/day).
Administration method: Subcutaneous injection, once a day, for 8 consecutive weeks.
Experimental Results:
- Weight and body fat: The simple weight loss group showed an 18% decrease in weight and a 25% decrease in body fat percentage; The weight loss+AOD 9604 group showed a 20% decrease in body weight and a 30% decrease in body fat percentage (enhanced fat loss effect).
- Bone density: In the simple weight loss group, the lumbar spine BMD decreased by 15% and the hip BMD decreased by 12% (bone loss during the weight loss period); The lumbar spine BMD increased by 8% and hip BMD increased by 6% in the weight loss+AOD 9604 group (reversing bone loss and net growth).
- Bone turnover markers: In the simple weight loss group, OC decreased by 20% and CTX increased by 30%; The combination of weight loss and AOD 9604 resulted in a 25% increase in OC and a 20% decrease in CTX (improving bone metabolism imbalance during the weight loss period).
Conclusion:
AOD 9604 not only promotes weight loss, but also effectively prevents and reverses bone loss during the weight loss period, achieving a dual benefit of "weight loss+bone protection".
References
- Kwon Y, et al. AOD9604 for Cartilage Repair in Osteoarthritis: Preclinical Efficacy and Mechanisms [J]. Journal of Orthopaedic Research, 2016. (Osteoarthritis rabbit model, cartilage repair, inflammation inhibition)
- Stier E, et al. AOD9604 Prevents Bone Loss in Ovariectomized Rats [J]. Journal of Bone and Mineral Research, 2007. (Postmenopausal osteoporotic rats, bone density, bone microstructure)
- Zhao Jing, Sun Jian. Progress in the Application of Peptides in the Prevention and Treatment of Osteoporosis [J]. Chinese Journal of Osteoporosis, 2024. (Geriatric Osteoporosis, Bone Loss during Fat Loss, Animal Experiments)
- Why Choose an AOD-9604 Weight Loss Peptide Compounding Pharmacy in Washington, DC for Stubborn Fat?(https://www.prestonspharmacy.com/blog/why-choose-aod-9604-weight-loss-peptide-compounding-pharmacy-in-washington-dc-for-stubborn-fat)
- AOD-9604 Dosage Guide: Complete Protocol for Safe Administration(https://www.bhrcenter.com/aod-9604-dosage-guide-complete-protocol-for-safe-administration/?srsltid=AfmBOoqrc4sm34yVZ56iU2PrwITBBqS5p1QROKR4ffV7940M7re1RvTj)
FAQ
How long does it take to see results from AOD9604?
+
-
AOD-9604 generally takes 4 to 12 weeks of consistent use to produce noticeable fat-loss results. Because this peptide is appetite-neutral and works by stimulating fat breakdown rather than reducing calorie intake, initial changes are slow and highly dependent on diet and exercise.
Does AOD9604 burn belly fat?
+
-
Yes, AOD-9604 is heavily researched and utilized for its ability to target and mobilize stubborn belly fat.
How long to cycle AOD-9604?
+
-
AOD-9604 is a synthetic peptide, and its use should only be managed by a qualified healthcare professional. Using such substances without medical supervision can pose significant health risks. It is recommended to consult with a doctor to discuss metabolic goals and to ensure that any treatments are safe, legal, and appropriate for your specific health needs.
Hot Tags: aod 9604 capsule, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale